viimane versioon :
19/11/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Viited 199
tüüp :
ajaleht
uurimisrühmad :
Baltimore - University of Maryland, School of Pharmacy
Autor :
Hassan E, Leslie J, Martir-Herrero ML.
pealkiri :
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
publikatsioon :
Am J Hosp Pharm ; 51: 2143-2145. 1994
Tõendite tase :
füüsikaline stabiilsus :
Keemiline püsivus :
Muud meetodid :
Kommentaarid :
ingredientide nimekiri
Dobutamine hydrochloride
2.5 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
Dopamine hydrochloride
1.6 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
Dobutamine hydrochloride
2.5 mg/ml
+
1 mg/ml
+
Dopamine hydrochloride
1.6 mg/ml
+
1 mg/ml
+
Morphine sulfate
0.5 mg/ml
+
1 mg/ml
+
Nitroglycerin
0.2 mg/ml
+
1 mg/ml
+
Ranitidine hydrochloride
0.6 mg/ml
+
Morphine sulfate
0.5 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
Nitroglycerin
0.2 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
Ranitidine hydrochloride
0.6 mg/ml
+
Labetalol hydrochloride
1 mg/ml
+
20°C-25°C
Labetalol hydrochloride
1 mg/ml
Dobutamine hydrochloride
2,5 mg/ml
4
20°C-25°C
Labetalol hydrochloride
1 mg/ml
Dopamine hydrochloride
1,6 mg/ml
4
20°C-25°C
Labetalol hydrochloride
1 mg/ml
Morphine sulfate
0,5 mg/ml
4
20°C-25°C
Labetalol hydrochloride
1 mg/ml
Nitroglycerin
0,2 mg/ml
4
20°C-25°C
Labetalol hydrochloride
1 mg/ml
Ranitidine hydrochloride
0,6 mg/ml
4
Mentions Légales
